Migdal Insurance & Financial Holdings Ltd. Black Diamond Therapeutics, Inc. Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.97 Billion
Q4 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 04, 2021	SELL	$12.19 - $28.17 $253,186 - $585,090	-20,770 Closed	0 $0
Q1 2021 May 04, 2021	BUY	$22.23 - $34.75 $286,522 - $447,892	12,889 Added 163.55%	20,770 $504,000
Q4 2020 Feb 08, 2021	BUY	$29.47 - $35.0 $232,253 - $275,835	7,881 New	7,881 $253,000

Others Institutions Holding BDTX

# of Institutions

Shares Held

47.4M

Call Options Held

2.9K

Put Options Held

69.4K

T. Rowe Price Investment Management, Inc. Baltimore, MD

10.5M
Shares

$15.1 Million
0.01% of portfolio
Bellevue Group Ag Kuesnacht, V8

8.52M
Shares

$12.3 Million
0.36% of portfolio
Vestal Point Capital, LP New York, NY

5.6M
Shares

$8.06 Million
0.71% of portfolio
Nea Management Company, LLC Timonium, MD

4.45M
Shares

$6.41 Million
0.68% of portfolio
Black Rock Inc. New York, NY

3.22M
Shares

$4.63 Million
0.0% of portfolio

View Full List

About Black Diamond Therapeutics, Inc.

Ticker BDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,339,500
Market Cap $52.3M
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...

More about BDTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account